Akums Drugs and Pharmaceuticals Limited (AKUMS) Price & Analysis

Compare

4 Followers

AKUMS Stock Chart & Stats

₹420.10

₹13.30(2.17%)

At close: Jan 08 4:00 PM EST

₹420.10

₹13.30(2.17%)

Day’s Range― - ―

52-Week Range₹407.40 - ₹620.00

Previous CloseN/A

Volume56.90K

Average Volume (3M)11.50K

Market Cap

₹78.87B

Enterprise Value₹70.61B

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)26.2

Beta1.47

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)4.33

Shares Outstanding157,393,980

10 Day Avg. Volume12,021

30 Day Avg. Volume11,497

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)2.32

Price to Sales (P/S)1.74

P/FCF Ratio36.67

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹680.00

Price Target Upside61.87% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)17.72

Revenue Forecast (FY)₹42.98B

Bulls Say, Bears Say

Bulls Say

Low LeverageA dramatic reduction in leverage materially improves financial flexibility and resilience. Lower debt cuts interest burden, increases capacity for capex, R&D or selective M&A, and strengthens credit metrics, supporting durable execution through industry cycles.

Strong Cash GenerationConsistent operating cash conversion and rising free cash flow underpin sustainable reinvestment into manufacturing, quality systems and product development. Robust cash coverage of earnings supports debt reduction, working capital and optional shareholder returns over the medium term.

Revenue And Margin RecoveryReturn to positive net margins and materially higher gross margin indicate improved pricing, cost control or product mix. Sustained margin expansion combined with revenue growth strengthens internal funding for R&D and capacity, enhancing long-term competitive positioning in generics and formulations.

Bears Say

Slowing Revenue GrowthA sharp deceleration in top-line growth signals potential saturation, pricing pressure or delayed new product uptake. If sustained, slower revenue expansion will constrain earnings leverage, reduce reinvestment capacity, and could expose the business to competitive share erosion over the medium term.

Compressing EBIT MarginDeclining EBIT margin points to rising operating costs or lower operational efficiency. Persisting margin compression would erode operating cash flow and limit ability to fund growth or absorb pricing shocks, weakening long-term profitability and competitive reinvestment capacity.

No Dividend YieldLack of a dividend policy reduces appeal to long-term income investors and can narrow the shareholder base. Over time this may increase reliance on growth to deliver returns, pressuring management priorities and potentially increasing stock volatility during downturns.

Akums Drugs and Pharmaceuticals Limited News

Akums Closes Trading Window Ahead of Q3 FY2025 Unaudited Results

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has issued an announcement. Akums Drugs and Pharmaceuticals Limited has...

2M ago

AKUMS

Akums Secures Patent for Innovative GERD Treatment

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has shared an announcement. Akums Drugs and Pharmaceuticals Limited has...

4M ago

AKUMS

Akums Drugs Expands with New Subsidiary in Malta

The latest update is out from Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ). Akums Drugs and Pharmaceuticals...

5M ago

AKUMS

Akums Expands with New Joint Venture in Zambia

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has issued an update. Akums Drugs and Pharmaceuticals Limited has...

5M ago

AKUMS

AKUMS FAQ

What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?

Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹407.40 and its highest was ₹620.00 in the past 12 months.

What is Akums Drugs and Pharmaceuticals Limited’s market cap?

Akums Drugs and Pharmaceuticals Limited’s market cap is ₹78.87B.

When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?

Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Jun 01, 2026 which is in 82 days.

How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?

Akums Drugs and Pharmaceuticals Limited released its earnings results on Feb 05, 2026. The company reported ₹4.332 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.332.

Is Akums Drugs and Pharmaceuticals Limited overvalued?

According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akums Drugs and Pharmaceuticals Limited pay dividends?

Akums Drugs and Pharmaceuticals Limited does not currently pay dividends.

What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?

Akums Drugs and Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?

Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.

What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?

Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹4.332 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.789%.

Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:AKUMS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, capsules, injectables, opthalmics, and soft gelatin capsules for therapeutic areas, such as gynaecology, cardiology, orthopaedics, pediatrics, and dermatology, as well as anti-infectives, pain management and gastroenterology. In addition, the company operates as pharmaceutical contract development and manufacturing company. The company was incorporated in 2004 and is based in Delhi, India.

Akums Drugs and Pharmaceuticals Limited (AKUMS) Earnings & Revenues

Historic Earnings Reports

AKUMS Stock 12 Month Forecast

Average Price Target

₹680.00

▲(61.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"423":"₹423","868":"₹868","534.25":"₹534.3","645.5":"₹645.5","756.75":"₹756.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":680,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹680.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":680,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹680.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":680,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹680.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[423,534.25,645.5,756.75,868],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Aug<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,474.25,490.0769230769231,505.90384615384613,521.7307692307693,537.5576923076923,553.3846153846154,569.2115384615385,585.0384615384615,600.8653846153846,616.6923076923076,632.5192307692307,648.3461538461538,664.1730769230769,{"y":680,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,474.25,490.0769230769231,505.90384615384613,521.7307692307693,537.5576923076923,553.3846153846154,569.2115384615385,585.0384615384615,600.8653846153846,616.6923076923076,632.5192307692307,648.3461538461538,664.1730769230769,{"y":680,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,474.25,490.0769230769231,505.90384615384613,521.7307692307693,537.5576923076923,553.3846153846154,569.2115384615385,585.0384615384615,600.8653846153846,616.6923076923076,632.5192307692307,648.3461538461538,664.1730769230769,{"y":680,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":791.7,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":791.7,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":832.65,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":867.6,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":841.1,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":617.3,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":633.5,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":633.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":455,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":514.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":424.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":437.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":474.25,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >